Modern advances in heart transplantation

• Published in: Progress in cardiovascular diseases Vol. 82; pp. 147 - 156
• Main Authors: Srivastava, Pratyaksh K., Kittleson, Michelle M.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01-01-2024
• Subjects: COVID-19; Guideline-directed medical therapy; Heart failure with reduced ejection fraction; CDC; WIT; Guideline-directed medical therapy; DPP; DBD; TPE; IVIg; Heart failure with reduced ejection fraction; COVID-19; MFI; CARGO; cPRA; IMAGE; NPV; EMB; WLST; CD; MP; DCD; D-OAR; AMR; IdeS; HTx; IL-6; ACR; CVD; ACS; ta-NRP; fWIT; GEP; HIV; SAB; dd-cfDNA; DNA; CAV; HLA; Ig; VA-ECMO
• ISSN: 0033-0620; 1532-8643
• DOI: 10.1016/j.pcad.2024.01.012

Heart transplantation (HTx) is the only definitive therapy for patients with end stage heart disease. With the increasing global prevalence of heart failure, the demand for HTx has continued to grow and outpace supply. In this paper, we will review advances in the field of HTx along the clinical journey of a HTx recipient. Starting with the sensitized patient, we discuss current methods to define sensitization, and assays to help identify clinically relevant anti-HLA antibodies. Desensitization strategies targeting all levels of the adaptive immune system are discussed with emphasis on novel techniques such as anti-CD 38 blockade and use of the Immunoglobulin G-Degrading Enzyme of Streptococcus Pyogenes. We next discuss donor procurement and the resurgence of donation after circulatory death as a viable strategy to significantly and safely increase the donor pool. Post-transplant, we evaluate non-invasive surveillance techniques including gene expression profiling and donor-derived cell-free DNA. Last, we discuss the ground-breaking developments in the field of xenotransplantation.